Reviews/Chronic Spontaneous Urticaria Treatment/Omalizumab relapse after withdrawal
Omalizumab · CSU-OMA-03 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Across several independent patient groups, stopping omalizumab is usually followed by symptoms coming back, and lasting drug-free remission is uncommon [1][13][16]. The strongest direct numbers come from one small single-centre report, where only 5% of 123 patients stopped after reaching remission and 75% needed more than one course of treatment [13]. Other groups treat the return of symptoms or the need to restart the drug as a common, predictable event [1][16], but none of them cleanly reports that more than half of patients relapsed. The largest group found that only half of those who stopped the drug later restarted it, and half had stopped on purpose because their disease was well controlled [11]. So the overall picture points firmly toward relapse being the usual outcome, while the exact 'most' figure is less solidly pinned down than it first appears.
Multiple independent primary cohorts and pooled trial analyses converge on the direction that symptom return is the expected outcome after omalizumab withdrawal and that durable off-drug remission is rare [1][13][16]. The clearest 'most' figures come from Denman [13], where only 5% of 123 patients stopped after achieving remission and 75% required more than one treatment course. Ferrer [1], pooling ASTERIA I, ASTERIA II and GLACIAL, confirms symptom return as a trial-observed phenomenon with rapid and slow categories. Marzano [16] and Litovsky [11] treat relapse and reintroduction as common, predictor-driven events, with Litovsky reporting discontinuation in 408 of 878 patients and reintroduction in 50% of them. The contested point: The evidence divides on the exact majority quantifier: no single primary study cleanly reports a relapse proportion above 50% for the target population. The clearest 'most' reading rides on Denman [13], the weakest design, while the most directly relevant study [16] gives no proportion and the largest cohort [11] shows reintroduction in only half of discontinuers, half of whom stopped electively.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only figures that read as 'most' (75% multiple courses, 5% durable remission) come from Denman [13], a single-centre correspondence letter (n=123) with no stated relapse definition, the weakest design in the included set.
The largest cohort, Litovsky [11], undercuts the claim: only 50% of discontinuers were reintroduced and half of discontinuations were elective ('achievement of a well-controlled disease'), so reintroduction is not equivalent to relapse.
Where it remains uncertain. The strongest 'most' figure comes from the weakest design [13], while the most relevant study reports no relapse proportion [16] and the largest cohort shows reintroduction in just 50% of discontinuers, half of them elective [11].
Aleatory
Symptom return after withdrawal varies across individuals and is categorised as rapid or slow [1], and relapse risk tracks with baseline factors such as disease duration and baseline UAS7 [16], so the outcome is not uniform across patients.
Epistemic
No single primary study in the corpus reports a relapse proportion above 50% for the target population; the most directly relevant study [16] gives no proportion, and the clearest figures sit in one small cohort [13].
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes that symptom return after discontinuation is a trial-confirmed phenomenon.
“Pivotal clinical trials have identified 2 categories of patients who experience symptom return: rapid and slow.”
Panel auditInternal validity: medium · scope of inference: Predictors of the speed of symptom return in antihistamine-refractory CSU patients who stop omalizumab.Key limitations: no relapse proportion reported · exploratory/post-hoc · 16-week follow-up only
Provides a reintroduction rate that both supports frequent relapse and tempers a strict-majority reading, since many discontinuations were elective.
“OMA was discontinued in 408 patients, but the drug was later reintroduced in 50% of them.”
Panel auditInternal validity: medium · scope of inference: Drug-survival and discontinuation/reintroduction patterns for omalizumab in French chronic urticaria patients.Key limitations: reintroduction is not relapse · retrospective · no relapse rate
Directly supports that relapse/retreatment is the common post-withdrawal outcome.
“Of our current cohort, 75% have had more than one treatment course”
Panel auditInternal validity: low · scope of inference: A single UK center's CSU cohort treated with omalizumab, including home self-administration.Key limitations: single-center observational · no stats · repeat course is a relapse proxy
Independent corroboration that relapse and retreatment occur, though without quantifying frequency.
“the efficacy of treatment was unchanged amongst patients who underwent a second series of treatment in cases of relapse”
Panel auditInternal validity: low · scope of inference: Biomarker prediction of omalizumab response in 46 CSU patients over 24 weeks.Key limitations: no relapse proportion · small single-center cohort
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent cohorts converge on frequent relapse after withdrawal, but no single primary study cleanly reports a >50% relapse proportion, warranting Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Prospective relapse proportion with a pre-specified definition. The corpus shows direction but no cohort cleanly reports what fraction of patients relapse after planned withdrawal [13][16][11], which is exactly what the 'most' claim requires. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective multicentre withdrawal cohort that pre-specifies a single relapse definition (symptom return above a set UAS7 threshold) and reports the proportion relapsing over a fixed follow-up.
Open question: What proportion of CSU patients relapse after planned omalizumab withdrawal under a single pre-specified relapse definition? Why it is still open: The clearest majority figures come from one small single-centre letter [13], the most relevant study reports no proportion [16], and the largest cohort reports only 50% reintroduction with half elective stops [11].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19